Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis

Mesalamine (5-ASA) is the mainstay therapy in patients with mild-to-moderate active ulcerative colitis (UC). However, non-adherence to therapy and practice variability among gastroenterologists represent long-standing barriers, leading to poor outcomes. Additionally, targets to treat in UC are incre...

Full description

Bibliographic Details
Main Authors: Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Journal of Clinical Medicine
Subjects:
ulcerative colitis
mild to moderate
5-aminosalicylate
budesonide multimatrix system
adherence
personalized medicine
Online Access:https://www.mdpi.com/2077-0383/9/9/2905

Internet

https://www.mdpi.com/2077-0383/9/9/2905

Similar Items